TY - STD TI - Novartis Pharmaceuticals: Gleevec prescribing information: Gleevec prescribing information. Novartis Pharmaceuticals Corporation website.http://www.pharma.us.novartis.com/product/pi/pdf/gleevec_tabs.pdf, UR - http://www.pharma.us.novartis.com/product/pi/pdf/gleevec_tabs.pdf ID - ref1 ER - TY - JOUR AU - Casali, P. G. AU - Blay, J. Y. PY - 2010 DA - 2010// TI - Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up JO - Ann Oncol VL - 21 UR - https://doi.org/10.1093/annonc/mdq208 DO - 10.1093/annonc/mdq208 ID - Casali2010 ER - TY - JOUR AU - Demetri, G. D. AU - von Mehren, M. AU - Antonescu, C. R. PY - 2010 DA - 2010// TI - NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors JO - J Natl Compr Canc Netw VL - 8 ID - Demetri2010 ER - TY - JOUR AU - Joensuu, H. AU - Eriksson, M. AU - Sundby Hall, K. PY - 2012 DA - 2012// TI - One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial JO - JAMA VL - 307 UR - https://doi.org/10.1001/jama.2012.347 DO - 10.1001/jama.2012.347 ID - Joensuu2012 ER - TY - STD TI - National Comprehensive Cancer Network: Clinical practice guidelines in oncology. Soft tissue sarcoma.http://www.nccn.org/professionals/physician_gls/f_guidelines.asp, UR - http://www.nccn.org/professionals/physician_gls/f_guidelines.asp ID - ref5 ER - TY - JOUR PY - 2012 DA - 2012// TI - ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up JO - Ann Oncol VL - 23 ID - ref6 ER - TY - JOUR AU - Joensuu, H. PY - 2008 DA - 2008// TI - Risk stratification of patients diagnosed with gastrointestinal stromal tumor JO - Hum Pathol VL - 39 UR - https://doi.org/10.1016/j.humpath.2008.06.025 DO - 10.1016/j.humpath.2008.06.025 ID - Joensuu2008 ER - TY - JOUR AU - Blay, J. Y. AU - Le Cesne, A. AU - Ray-Coquard, I. PY - 2007 DA - 2007// TI - Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2006.09.0183 DO - 10.1200/JCO.2006.09.0183 ID - Blay2007 ER - TY - JOUR AU - Demetri, G. D. AU - Wang, Y. AU - Wehrle, E. PY - 2007 DA - 2007// TI - Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.20.4818 DO - 10.1200/JCO.2008.20.4818 ID - Demetri2007 ER - TY - JOUR AU - Joensuu, H. AU - Trent, J. C. AU - Reichardt, P. PY - 2011 DA - 2011// TI - Practical management of tyrosine kinase inhibitor-associated side effects in GIST JO - Cancer Treat Rev VL - 37 UR - https://doi.org/10.1016/j.ctrv.2010.04.008 DO - 10.1016/j.ctrv.2010.04.008 ID - Joensuu2011 ER - TY - JOUR AU - von Mehren, M. AU - Heinrich, M. C. AU - Joensuu, H. PY - 2011 DA - 2011// TI - Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or resectable KIT+ gastrointestinal stromal tumors (GIST) JO - J Clin Oncol VL - 29 ID - von Mehren2011 ER -